Dida Francis, Li Yufeng, Iwao Atsushi, Deguchi Takao, Azuma Eiichi, Komada Yoshihiro
Department of Pediatrics and Developmental Science, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Exp Hematol. 2008 Oct;36(10):1343-53. doi: 10.1016/j.exphem.2008.04.011. Epub 2008 Jul 2.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily, which induces apoptosis in cancer cells but not in normal cells. Akt/protein kinase B, when phosphorylated to its active form, promotes cell survival and blocks apoptosis. The aim of this study was to investigate the role of Akt pathway in acquired TRAIL resistance of acute lymphoblastic leukemia cells.
MB-IT and NALM-24 cells that developed resistance to TRAIL, i.e., TRAIL-resistant cells (MB-IT R and NALM-24 R) were established from TRAIL-sensitive acute lymphoblastic leukemia cell lines (MB-IT S and NALM-24 S), respectively, through application of TRAIL and repetitive limiting dilution. Apoptosis was measured by flow cytometry using propidium iodide/Annexin-V fluorescein isothiocyanate staining. TRAIL receptor cell surface expression of MB-IT and NALM-24 were analyzed by flow cytometry. Protein levels were analyzed by Western blot analysis.
The obtained resistant cell lines presented the same pattern of receptor expression as sensitive parent cells, and the internalization of DR5 after TRAIL treatment was similar. Caspase-8/3, FLIP, BID, XIAP were cleaved/downregulated in sensitive cells after treatment with TRAIL, but not in the resistant cells. We also observed that phosphoinositide-3-kinase (PI3K)/Akt pathway was constitutively active in resistant clones, and was not downregulated upon TRAIL treatment. Phosphate and tensin homologue deleted on chromosome 10 (PTEN) level was the same in both sensitive cells and resistant cells, but was quickly downregulated in sensitive cells after TRAIL treatment. Also, resistant cells expressed a high level of phosphorylated inactive form of PTEN than the sensitive cells. Expression levels of PH domain leucine-rich repeat protein phosphatase were slightly higher in sensitive than resistant cells. When resistant cells were treated with LY 294002 (a PI3K inhibitor), the expression level of phosphorylated Akt was distinctly downregulated, and there was induction of apoptosis when these cells were treated with a combination of TRAIL and LY 294002. When MB-IT-sensitive cells were treated with okadaic acid, a phosphatase inhibitor, TRAIL-induced apoptosis was significantly reduced.
These results suggest that cellular resistance to TRAIL could be developed through phosphorylation (activation) of Akt and phosphorylation (inactivation) of PTEN.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)是肿瘤坏死因子超家族的成员,可诱导癌细胞凋亡,但不诱导正常细胞凋亡。Akt/蛋白激酶B磷酸化成为其活性形式时,可促进细胞存活并阻止凋亡。本研究旨在探讨Akt信号通路在急性淋巴细胞白血病细胞获得性TRAIL耐药中的作用。
通过应用TRAIL和重复有限稀释法,分别从对TRAIL敏感的急性淋巴细胞白血病细胞系(MB-IT S和NALM-24 S)中建立对TRAIL耐药的MB-IT和NALM-24细胞,即TRAIL耐药细胞(MB-IT R和NALM-24 R)。采用碘化丙啶/异硫氰酸荧光素标记的膜联蛋白V通过流式细胞术检测凋亡情况。通过流式细胞术分析MB-IT和NALM-24的TRAIL受体细胞表面表达。采用蛋白质印迹分析检测蛋白质水平。
获得的耐药细胞系与敏感亲本细胞呈现相同的受体表达模式,TRAIL处理后DR5的内化情况相似。TRAIL处理后,敏感细胞中的半胱天冬酶-8/3、FLIP、BID和XIAP被切割/下调,但耐药细胞中未出现这种情况。我们还观察到,磷酸肌醇-3-激酶(PI3K)/Akt信号通路在耐药克隆中持续激活,TRAIL处理后未下调。10号染色体缺失的磷酸酶和张力蛋白同源物(PTEN)水平在敏感细胞和耐药细胞中相同,但TRAIL处理后敏感细胞中的PTEN水平迅速下调。此外,耐药细胞中磷酸化的无活性形式的PTEN表达水平高于敏感细胞。富含亮氨酸重复序列的PH结构域蛋白磷酸酶的表达水平在敏感细胞中略高于耐药细胞。当耐药细胞用LY 294002(一种PI3K抑制剂)处理时,磷酸化Akt的表达水平明显下调,当这些细胞用TRAIL和LY 294002联合处理时会诱导凋亡。当MB-IT敏感细胞用磷酸酶抑制剂冈田酸处理时,TRAIL诱导的凋亡显著减少。
这些结果表明,细胞对TRAIL的耐药可能通过Akt的磷酸化(激活)和PTEN的磷酸化(失活)产生。